Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses

v3.10.0.1
Accrued Expenses
 6 Months Ended
Jun. 30, 2018
Payables and Accruals [Abstract]  
Accrued Expenses

7. ACCRUED EXPENSES

 

Accrued expenses consisted of the following:

 

    June 30, 2018     December 31, 2017  
             
Accrued clinical operations and trials costs   $ 3,515,639     $ 2,003,799  
Accrued product development costs     1,197,250       1,255,439  
Accrued compensation     916,626       1,335,672  
Accrued other     175,300       146,609  
Total   $ 5,804,815     $ 4,741,519